CDKN2A and neoplasm: Based on results from the OncomineTM Immune Response Research Assay, the expressions of the immune markers ARG1 and HLA-DQB2 and the tumour markers CDKN2A and KRT7 were evaluated via qPCR in a cohort of 264 biopsies with normal, CIN1, CIN2, or CIN3 biopsies in the follow-up of women with abnormal cytology and/or hrHPV infection at baseline cytology.